Internship

Brand Marketing Intern

Posted on 12/20/2024

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Biotechnology
Healthcare

San Diego, CA, USA

Category
Brand & Creative Marketing
Growth & Marketing
Required Skills
Branding/Brand Strategy
Marketing
Data Analysis
Requirements
  • Strong understanding of marketing concepts is required to succeed in this role
  • Ability to think critically and creatively
  • Excellent verbal and written communication skills
  • Foundational marketing experience
  • Willingness to adapt and work collaboratively on multiple projects
  • Ability to commit to a 10-week, full-time summer program
  • Pursuing an undergraduate degree with an interest in biotechnology
  • Undergraduate degree in Marketing or related field
  • Prior experience in the pharmaceutical or biotechnology industry a plus
  • Familiarity with biopharmaceutical technologies, physical and life sciences, product development, and regulatory approval processes
Responsibilities
  • Contribute to ongoing marketing activities such as brand strategy, tactical execution, and promotional materials for the INGREZZA® commercial business
  • Support the marketing team in various tasks related to campaign management, digital promotions, insights & analytics, asset development, and agency partnerships
  • Participate in annual strategic and tactical planning for INGREZZA®
  • Partner with the broader commercial organization including Commercial Analytics, Field Sales, Corporate Communications, Market Access, Medical, Regulatory, and more
  • Collaborate with a mentor team of cross-functional partners and the other interns in the class
  • Complete a special project and present recommendations to senior management upon completion
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval of CRENESSITY opens a new market for CAH treatment.
  • Positive Phase 2 data for NBI-1117568 shows promise in schizophrenia treatment.
  • Significant investments from Aigen and Mediolanum indicate strong investor confidence.

What critics are saying

  • Increased competition in CAH treatment may challenge CRENESSITY's market position.
  • Potential strategic shifts with new CEO Kyle Gano could impact company direction.
  • Reliance on FDA approvals poses risks if delays or rejections occur.

What makes Neurocrine Biosciences unique

  • CRENESSITY is the first new CAH treatment in 70 years.
  • Neurocrine's INGREZZA sprinkle formulation addresses dysphagia in patients with Huntington's disease.
  • Neurocrine is recognized as a top workplace in biopharma, ranking No. 7 in 2024.

Help us improve and share your feedback! Did you find this helpful?